These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

400 related articles for article (PubMed ID: 33428078)

  • 1. Immunotherapy-induced pneumonitis in non-small cell lung cancer patients: current concern in treatment with immune-check-point inhibitors.
    Sun Z; Wang S; Du H; Shen H; Zhu J; Li Y
    Invest New Drugs; 2021 Jun; 39(3):891-898. PubMed ID: 33428078
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune-induced pneumonia in patients with advanced solid tumors treated with immunotherapy: a real-world assessment.
    Wang C; Zhu H; Huang H; Sun Z; Teng Y; Li Y
    Future Oncol; 2023 Jan; 19(3):259-270. PubMed ID: 36891950
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome and risk factor of immune-related adverse events and pneumonitis in patients with advanced or postoperative recurrent non-small cell lung cancer treated with immune checkpoint inhibitors.
    Isono T; Kagiyama N; Takano K; Hosoda C; Nishida T; Kawate E; Kobayashi Y; Ishiguro T; Takaku Y; Kurashima K; Yanagisawa T; Takayanagi N
    Thorac Cancer; 2021 Jan; 12(2):153-164. PubMed ID: 33201587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors.
    Suresh K; Voong KR; Shankar B; Forde PM; Ettinger DS; Marrone KA; Kelly RJ; Hann CL; Levy B; Feliciano JL; Brahmer JR; Feller-Kopman D; Lerner AD; Lee H; Yarmus L; D'Alessio F; Hales RK; Lin CT; Psoter KJ; Danoff SK; Naidoo J
    J Thorac Oncol; 2018 Dec; 13(12):1930-1939. PubMed ID: 30267842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anaplastic lymphoma kinase inhibitor related pneumonitis in patients with non-small cell lung cancer: Clinical and radiologic characteristics and risk factors.
    Hwang HJ; Kim MY; Choi CM; Lee JC
    Medicine (Baltimore); 2019 Nov; 98(48):e18131. PubMed ID: 31770246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Computed tomography-based radiomics for the differential diagnosis of pneumonitis in stage IV non-small cell lung cancer patients treated with immune checkpoint inhibitors.
    Tohidinezhad F; Bontempi D; Zhang Z; Dingemans AM; Aerts J; Bootsma G; Vansteenkiste J; Hashemi S; Smit E; Gietema H; Aerts HJ; Dekker A; Hendriks LEL; Traverso A; De Ruysscher D
    Eur J Cancer; 2023 Apr; 183():142-151. PubMed ID: 36857819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment- and immune-related adverse events of immune checkpoint inhibitors in advanced lung cancer.
    Shao J; Wang C; Ren P; Jiang Y; Tian P; Li W
    Biosci Rep; 2020 May; 40(5):. PubMed ID: 32315071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials.
    Khunger M; Rakshit S; Pasupuleti V; Hernandez AV; Mazzone P; Stevenson J; Pennell NA; Velcheti V
    Chest; 2017 Aug; 152(2):271-281. PubMed ID: 28499515
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and radiological features of immune checkpoint inhibitor-related pneumonitis in lung cancer and non-lung cancers.
    Nobashi TW; Nishimoto Y; Kawata Y; Yutani H; Nakamura M; Tsuji Y; Yoshida A; Sugimoto A; Yamamoto T; Alam IS; Noma S
    Br J Radiol; 2020 Nov; 93(1115):20200409. PubMed ID: 32783627
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative incidence of immune-related adverse events and hyperprogressive disease in patients with non-small cell lung cancer receiving immune checkpoint inhibitors with and without chemotherapy.
    Matsuo N; Azuma K; Kojima T; Ishii H; Tokito T; Yamada K; Hoshino T
    Invest New Drugs; 2021 Aug; 39(4):1150-1158. PubMed ID: 33483882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radiographic features and prognosis of early- and late-onset non-small cell lung cancer immune checkpoint inhibitor-related pneumonitis.
    Huang A; Xu Y; Zang X; Wu C; Gao J; Sun X; Xie M; Ma X; Deng H; Song J; Ren F; Pang L; Qian J; Yu Z; Wan S; Chen Y; Pan L; Zhuang G; Liu S; Xue X
    BMC Cancer; 2021 May; 21(1):634. PubMed ID: 34051746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of interstitial lung disease associated with immune checkpoint inhibitors on prognosis in patients with non-small-cell lung cancer.
    Yamagata A; Yokoyama T; Fukuda Y; Ishida T
    Cancer Chemother Pharmacol; 2021 Feb; 87(2):251-258. PubMed ID: 33394102
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune Checkpoint Inhibitors and Cardiac Toxicity in Patients Treated for Non-Small Lung Cancer: A Review.
    Sławiński G; Wrona A; Dąbrowska-Kugacka A; Raczak G; Lewicka E
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 33003425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clarification of Definitions of Hyperprogressive Disease During Immunotherapy for Non-Small Cell Lung Cancer.
    Kas B; Talbot H; Ferrara R; Richard C; Lamarque JP; Pitre-Champagnat S; Planchard D; Balleyguier C; Besse B; Mezquita L; Lassau N; Caramella C
    JAMA Oncol; 2020 Jul; 6(7):1039-1046. PubMed ID: 32525513
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
    Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
    Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The association between the incidence risk of pneumonitis and PD-1/PD-L1 inhibitors in advanced NSCLC: A meta-analysis of randomized controlled trials.
    Lin GF; Xu Y; Lin H; Yang DY; Chen L; Huang LL; Su XS; Xu YX; Zeng YM
    Int Immunopharmacol; 2021 Oct; 99():108011. PubMed ID: 34426108
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study.
    Okada N; Matsuoka R; Sakurada T; Goda M; Chuma M; Yagi K; Zamami Y; Nishioka Y; Ishizawa K
    Sci Rep; 2020 Aug; 10(1):13773. PubMed ID: 32792640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Checkpoint Inhibition With Chemoradiotherapy in Stage III Non-small-cell Lung Cancer: A Systematic Review and Meta-analysis of Safety Results.
    Balasubramanian A; Onggo J; Gunjur A; John T; Parakh S
    Clin Lung Cancer; 2021 Mar; 22(2):74-82. PubMed ID: 33414053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
    Ruste V; Goldschmidt V; Laparra A; Messayke S; Danlos FX; Romano-Martin P; Champiat S; Voisin AL; Baldini C; Massard C; Laghouati S; Marabelle A; Lambotte O; Michot JM
    Eur J Cancer; 2021 Nov; 158():217-224. PubMed ID: 34627664
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.